Unternehmensprofil der M1 Kliniken AG
Unternehmensprofil der M1 Kliniken AG

Unique business model

Company profile

M1 Kliniken AG, based in Berlin, is one of the fastest growing and leading private providers of health services in the beauty sector. With its products and services, the group of companies with more than 350 employees offers a customer-oriented spectrum of aesthetic and surgical treatments throughout Germany. Our experienced and highly specialised team uses high-quality products and state-of-the-art medical technology to perform more than 400,000 minimally invasive and surgical procedures every year to the highest quality standards.

Business model

With the guiding principle "highest quality at the best price", M1 started in 2012 and has established itself as the market leader for beauty medicine in Germany. M1 aims to achieve this leading position in the international beauty segment as well by constantly expanding abroad.

To realize this vision, M1 has developed a unique business model, which is based on specialisation and thus providing the highest quality in medicine. Experts agree on this and for us, top medicine through specialisation is the corporate DNA. M1 Kliniken is the first company to focus on selected treatments within aesthetic and plastic medicine. The results are economies of scale and affordable prices.

More than 100 highly specialized doctors perform more treatments in their field of specialty than regular doctors. This routine increases safety for our clients. Our own training and further education at the M1 Akademie also contributes to this. At the same time, centralised purchasing enables us to use the most modern technical infrastructure and the highest quality products and medicines at attractive prices. With this specialisation, M1 makes top medicine accessible to the general public.

> 350 employees

> 1.000,000 treatments

> 60 specialist centres worldwide

Latest news

Beauty segment: profitability again significantly increased

  • Revenue: +5.7% to EUR 27.1 million (Q1 2025: EUR 25.6 million)
  • EBIT: +37.6% to EUR 9.2 million (Q1 2025: EUR 6.7 million)
  • EBIT margin: 33.9% (Q1 2025: 26.0%)

Group figures: shaped by the sale of HAEMATO Pharm GmbH

  • Group revenue: EUR 46.8 million (Q1 2025: EUR 92.7 million)
  • EBIT: EUR 5.0 million (Q1 2025: EUR 8.8 million)

| Investor News

M1 Kliniken AG (ISIN DE000A0STSQ8) has cancelled the treasury shares acquired under its share buyback programme and reduced its share capital accordingly.

On 25 March 2026, the Management Board resolved, with the approval of the Supervisory Board granted on 26 March 2026 and on the basis of the authorisation by the Annual General Meeting of 17 July 2024, to reduce the Company's share capital by EUR 1,088,289 from EUR 19,643,403 to EUR 18,555,114. The capital reduction became effective upon registration in the commercial register of the Local Court of Charlottenburg (HRB 107637 B) on 26 May 2026.

| Investor News

Group key figures at a glance

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)

| Ad-hoc news

At today's balance sheet meeting, the Supervisory Board of M1 Kliniken AG (ISIN: DE000A0STSQ8) approved the annual financial statements and the consolidated financial statements of the Company for the 2025 financial year, as submitted by the Management Board, in accordance with §§ 171, 172 AktG. The annual financial statements are thereby adopted pursuant to § 172 AktG.

The Supervisory Board and the Management Board today resolved to propose to the Annual General Meeting a dividend of EUR 1.20 per dividend-bearing share.

The 2025 Annual Report of M1 Kliniken AG is expected to be published on 20 May 2026.